종양 침윤 림프구 치료제(TIL 치료제) 시장 : 전략적 인사이트 및 예측(2026-2031년)

The Tumor-Infiltrating Lymphocyte (TIL) Therapy Market is set to reach USD 550.494 million in 2031, growing at a CAGR of 10.6 % from USD 332.51 million in 2026.

The global tumor infiltrating lymphocyte (TIL) therapy market is experiencing significant expansion as healthcare systems increasingly adopt advanced immunotherapy solutions for the treatment of solid tumors and refractory cancers. Tumor infiltrating lymphocyte therapy is a type of adoptive cell therapy that utilizes immune cells naturally present within a patient's tumor microenvironment. These lymphocytes are isolated from tumor tissue, expanded ex vivo, and reinfused into the patient to stimulate targeted anti-tumor immune responses. TIL therapy has emerged as a promising treatment approach for patients with advanced cancers who have limited response to conventional therapies and checkpoint inhibitors.

The increasing global burden of cancer remains one of the primary growth drivers for the market. Rising incidences of melanoma, cervical cancer, lung cancer, colorectal cancer, ovarian cancer, and head and neck cancers are increasing demand for innovative immunotherapy solutions capable of improving treatment outcomes. Conventional therapies such as chemotherapy and radiation therapy often face limitations related to systemic toxicity, tumor resistance, and disease recurrence. TIL therapies are increasingly being adopted because they offer personalized and targeted immune-mediated anti-cancer activity with the potential for durable clinical responses.

The growing adoption of personalized medicine and precision oncology is significantly supporting market expansion. TIL therapy utilizes patient-derived immune cells, enabling highly individualized treatment strategies tailored to the patient's tumor biology and immune profile. Precision medicine initiatives integrating genomic profiling, biomarker analysis, and molecular diagnostics are further strengthening the role of cellular immunotherapies in oncology treatment planning.

Technological advancements in cell expansion technologies, tumor profiling, gene editing, and cell manufacturing platforms are transforming the TIL therapy market. Automated manufacturing systems, improved lymphocyte isolation methods, and optimized cell culture technologies are enhancing production efficiency and scalability. Researchers are increasingly investigating genetically modified TILs, combination immunotherapy approaches, and next-generation cell engineering technologies to improve therapeutic efficacy and persistence.

The market is also benefiting from increasing pharmaceutical and biotechnology investment in immuno-oncology research and adoptive cell therapy development. Companies are expanding clinical trial programs focused on TIL therapies for solid tumors and combination treatment approaches involving checkpoint inhibitors, cytokine therapies, and targeted agents. Strategic collaborations between biotechnology firms, cancer research institutes, and healthcare providers are accelerating innovation in personalized immunotherapy solutions.

Growing regulatory support and increasing awareness regarding cellular immunotherapy are further contributing to market growth. Regulatory agencies are increasingly supporting development of advanced immunotherapies through accelerated approval pathways and orphan drug designations. Healthcare providers and oncology centers are also expanding investment in specialized cell therapy infrastructure and accredited treatment facilities to support broader clinical adoption.

North America currently dominates the tumor infiltrating lymphocyte therapy market due to advanced biotechnology infrastructure, strong oncology research capabilities, and significant investment in immunotherapy innovation. Europe also represents a substantial market supported by increasing precision medicine initiatives and expanding cancer research programs. Asia Pacific is expected to witness rapid growth due to rising healthcare expenditure, increasing cancer burden, and expanding biotechnology investment in countries such as China, Japan, South Korea, and India.

Despite strong growth prospects, the market faces challenges related to high treatment costs, manufacturing complexity, limited scalability, and therapy-related adverse events. However, ongoing advancements in automated cell manufacturing, genomic medicine, and combination immunotherapy strategies are expected to create substantial long-term growth opportunities for the tumor infiltrating lymphocyte therapy market.

Market Drivers

Increasing Prevalence of Solid Tumors

The growing global incidence of solid tumors is one of the major drivers of the tumor infiltrating lymphocyte therapy market. Rising cases of melanoma, cervical cancer, lung cancer, colorectal cancer, and ovarian cancer are increasing demand for advanced immunotherapy solutions capable of improving patient survival outcomes.

TIL therapies have demonstrated promising clinical effectiveness in patients with advanced and treatment-resistant cancers, particularly in melanoma and cervical cancer. Expanding clinical evidence supporting durable therapeutic responses is accelerating physician adoption and clinical research activity.

Growing Adoption of Personalized Immunotherapy

The increasing focus on personalized medicine and targeted oncology is significantly supporting market growth. TIL therapies are developed using patient-derived immune cells, enabling highly individualized treatment approaches tailored to tumor-specific immune responses.

Healthcare providers are increasingly adopting personalized immunotherapies to improve treatment precision, reduce recurrence risk, and enhance long-term therapeutic effectiveness.

Advancements in Cell Expansion and Manufacturing Technologies

Continuous innovation in cell isolation, lymphocyte expansion, automated manufacturing, and cell engineering technologies is positively influencing the market. Improved manufacturing platforms are enhancing scalability, reducing contamination risk, and improving production consistency.

Automated and closed-system manufacturing technologies are expected to reduce production timelines and improve broader accessibility of TIL therapies across healthcare systems.

Increasing Investment in Immuno-Oncology Research

Pharmaceutical companies, biotechnology firms, and research institutions are significantly increasing investment in TIL therapy clinical trials and immuno-oncology research. Researchers are evaluating TIL therapies across multiple solid tumor indications and combination treatment strategies.

Combination approaches involving checkpoint inhibitors, cytokine therapies, and targeted agents are demonstrating promising clinical potential and expanding future therapeutic opportunities.

Growing Regulatory Support for Cell Therapies

Regulatory agencies are increasingly supporting development of advanced cell therapies through accelerated review programs, orphan drug designations, and regenerative medicine frameworks.

Increasing regulatory approvals for adoptive cell therapies and expanding healthcare investment in oncology infrastructure are improving long-term market growth prospects.

Market Restraints

High Cost of TIL Therapy

One of the major restraints affecting the tumor infiltrating lymphocyte therapy market is the high cost associated with treatment and individualized manufacturing processes. TIL therapy involves tumor tissue extraction, lymphocyte isolation, cell expansion, and reinfusion procedures requiring specialized infrastructure and technical expertise.

High treatment expenses may limit patient accessibility and create reimbursement challenges, particularly in emerging healthcare markets.

Complex and Time-Intensive Manufacturing Process

TIL therapy production involves multiple complex steps including surgical tumor extraction, ex vivo lymphocyte expansion, quality control testing, and reinfusion. The manufacturing process can be lengthy and resource-intensive.

Coordinating individualized production workflows and maintaining consistent manufacturing quality may limit scalability and broader clinical adoption.

Therapy-Related Adverse Events

TIL therapies may be associated with adverse effects related to lymphodepleting chemotherapy, cytokine administration, and immune activation. Patients may experience cytokine-related toxicities, immune complications, and treatment-related side effects requiring specialized monitoring.

Management of adverse events often requires administration within accredited oncology centers equipped for intensive supportive care.

Limited Commercialization and Infrastructure Availability

TIL therapies currently remain available in limited healthcare centers with specialized cell therapy infrastructure and manufacturing capabilities. Limited treatment center availability may restrict patient access in certain regions.

Healthcare systems may require substantial investment in cell processing facilities, skilled personnel, and regulatory compliance systems to support broader adoption.

Technology and Segment Insights

The tumor infiltrating lymphocyte therapy market is segmented by therapy type, cancer indication, end-user, and geography. By therapy type, the market includes autologous TIL therapy, genetically modified TIL therapy, and combination TIL therapies. Autologous TIL therapy currently dominates the market because of its established clinical development and growing utilization in melanoma treatment.

Genetically modified TIL therapies are also witnessing increasing interest due to advancements in gene editing technologies and efforts to improve therapeutic persistence and anti-tumor activity.

Based on cancer indication, the market includes melanoma, cervical cancer, lung cancer, colorectal cancer, ovarian cancer, head and neck cancer, and others. Melanoma currently accounts for the largest market share due to strong clinical evidence supporting TIL therapy effectiveness in advanced melanoma patients.

Cervical cancer and lung cancer are also emerging application areas because of increasing clinical trial activity and growing interest in solid tumor immunotherapy approaches.

By end-user, the market includes hospitals, cancer treatment centers, academic and research institutions, and specialty oncology clinics. Hospitals and specialized cancer treatment centers currently account for a substantial market share due to the complex clinical management and infrastructure requirements associated with TIL therapy administration.

Academic and research institutions are also major contributors due to increasing involvement in immunotherapy clinical trials and translational oncology research.

Regionally, North America dominates the market due to advanced biotechnology ecosystems, strong oncology research infrastructure, and substantial healthcare investment in immunotherapy innovation. Europe continues to witness significant growth supported by increasing precision medicine initiatives and expanding oncology clinical research. Asia Pacific is expected to experience rapid expansion due to improving healthcare infrastructure, rising cancer burden, and increasing biotechnology investment.

Competitive and Strategic Outlook

The tumor infiltrating lymphocyte therapy market is highly competitive and characterized by the presence of biotechnology companies, immunotherapy developers, and oncology research organizations. Key market participants include Iovance Biotherapeutics, Inc., Achilles Therapeutics plc, Instil Bio, Inc., Obsidian Therapeutics, Inc., Turnstone Biologics Corp., Genocea Biosciences, Inc., BioNTech SE, Merck & Co., Inc., Bristol Myers Squibb Company, and F. Hoffmann-La Roche Ltd.

Leading companies are increasingly focusing on next-generation TIL therapies, automated manufacturing platforms, and combination immunotherapy approaches to strengthen market positioning. Investments in gene editing technologies, AI-driven biomarker discovery, and advanced cell engineering are accelerating across the industry.

Iovance Biotherapeutics continues to maintain a strong market position through clinical development of lifileucel and expansion of TIL manufacturing capabilities. Biotechnology firms are increasingly evaluating TIL therapies in combination with checkpoint inhibitors and targeted therapies to improve treatment efficacy in solid tumors.

Strategic collaborations between biotechnology companies, pharmaceutical manufacturers, and cancer research institutions are accelerating innovation in adoptive cell therapy development. Companies are also increasingly investing in decentralized manufacturing platforms and automated production systems to improve scalability and patient accessibility.

The market is witnessing growing focus on improving therapeutic durability, reducing manufacturing complexity, and expanding applications across multiple solid tumor indications. Companies capable of improving manufacturing efficiency, clinical outcomes, and treatment accessibility are expected to strengthen long-term market competitiveness.

Conclusion

The global tumor infiltrating lymphocyte therapy market is expected to witness strong growth due to increasing cancer prevalence, rising adoption of personalized immunotherapy, and continuous advancements in cellular therapy technologies.

TIL therapy is transforming solid tumor treatment by enabling personalized and targeted immune-mediated anti-cancer responses using patient-derived lymphocytes. Growing investment in immuno-oncology research, genomic medicine, and advanced cell manufacturing technologies is further strengthening market expansion.

Technological advancements in automated cell processing, gene editing, biomarker analysis, and combination immunotherapy strategies are significantly improving therapeutic innovation and clinical potential. However, challenges related to high treatment costs, manufacturing complexity, therapy-related adverse events, and limited treatment infrastructure continue to affect broader market adoption.

Despite these restraints, ongoing innovation in adoptive cell therapy, personalized oncology, and precision immunotherapy is expected to create substantial long-term growth opportunities for the tumor infiltrating lymphocyte therapy market.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Tumor-Infiltrating Lymphocyte Therapy Market Definition and Scope
• 1.2 Key Market Insights and Cell Therapy Adoption Trends
• 1.3 Clinical Development and Commercialization Snapshot
• 1.4 Probability-Adjusted Market Growth Outlook
• 1.5 Strategic Takeaways

2. Tumor-Infiltrating Lymphocyte Therapy Market Overview

• 2.1 Market Definition and Structure
• 2.2 Tumor-Infiltrating Lymphocyte Therapy Market Size Analysis 2021-2025
• 2.3 Tumor-Infiltrating Lymphocyte Therapy Market Size Forecast 2026-2031
• 2.4 Market Drivers
  • 2.4.1 Increasing Clinical Validation of Personalized Cell Therapies
  • 2.4.2 Expansion Beyond Melanoma into Solid Tumors
  • 2.4.3 Advancements in Manufacturing and Automation
  • 2.4.4 Favorable Regulatory Support for Advanced Therapies
• 2.5 Market Restraints
  • 2.5.1 Complex Autologous Manufacturing Processes
  • 2.5.2 High Treatment Cost and Infrastructure Requirements
  • 2.5.3 Limited Specialized Treatment Centers
• 2.6 Market Opportunities
  • 2.6.1 Expansion into Cervical, Lung, and Gastrointestinal Cancers
  • 2.6.2 Combination with Checkpoint Inhibitors
  • 2.6.3 Development of Next-Generation TIL Platforms
• 2.7 Tumor-Infiltrating Lymphocyte Therapy Market Segmentation
  • 2.7.1 By Cancer Type
    • 2.7.1.1 Melanoma
    • 2.7.1.2 Cervical Cancer
    • 2.7.1.3 Non-Small Cell Lung Cancer
    • 2.7.1.4 Ovarian Cancer
    • 2.7.1.5 Head and Neck Cancer
    • 2.7.1.6 Others
  • 2.7.2 By Therapy Type
    • 2.7.2.1 Autologous TIL Therapy
    • 2.7.2.2 Genetically Modified TIL Therapy
    • 2.7.2.3 Combination TIL Therapy
  • 2.7.3 By Treatment Setting
    • 2.7.3.1 Inpatient
    • 2.7.3.2 Outpatient
  • 2.7.4 By End User
    • 2.7.4.1 Academic Medical Centers
    • 2.7.4.2 Specialty Cancer Hospitals
    • 2.7.4.3 Cell Therapy Centers

3. Epidemiology and Disease Burden

• 3.1 Global Cancer Burden Addressable by TIL Therapy
• 3.2 Melanoma Epidemiology
• 3.3 Cervical Cancer Epidemiology
• 3.4 Lung Cancer Epidemiology
• 3.5 Future Eligible Patient Population Analysis

4. Disease and Unmet Need Analysis

• 4.1 Limitations of Existing Immunotherapies
• 4.2 Unmet Need in Checkpoint-Refractory Solid Tumors
• 4.3 Need for Personalized Cell Therapy Approaches
• 4.4 Barriers to Broad Patient Access
• 4.5 Demand for Durable Responses in Advanced Disease

5. Technology and Treatment Landscape

• 5.1 TIL Therapy Mechanism of Action
• 5.2 Tumor Harvest and Cell Expansion Workflow
• 5.3 Lymphodepletion and IL-2 Support Regimens
• 5.4 Manufacturing and Quality Control Processes
• 5.5 Automation and Closed-System Production
• 5.6 Next-Generation Gene-Edited TIL Approaches

6. Clinical Development and Pipeline Landscape

• 6.1 Clinical Trial Activity
• 6.2 Pipeline Distribution by Development Phase
  • 6.2.1 Preclinical
  • 6.2.2 Phase I
  • 6.2.3 Phase II
  • 6.2.4 Phase III
  • 6.2.5 Filed and Under Regulatory Review
• 6.3 Pipeline Distribution by Cancer Type
• 6.4 Pipeline Distribution by Therapy Type
• 6.5 Clinical Trial Design Benchmarking
  • 6.5.1 Sample Size Analysis
  • 6.5.2 Endpoint Assessment
  • 6.5.3 Recruitment Timelines
  • 6.5.4 Duration Analysis
• 6.6 Success and Failure Rate Analysis
• 6.7 Attrition Trends in Cell Therapy Programs
• 6.8 Regulatory Designations and Accelerated Pathways

7. Pipeline Asset Benchmarking

• 7.1 Melanoma TIL Assets
• 7.2 Cervical Cancer TIL Assets
• 7.3 Lung Cancer TIL Assets
• 7.4 Ovarian Cancer TIL Assets
• 7.5 Gene-Modified TIL Programs
• 7.6 First-in-Class vs Best-in-Class Assessment
• 7.7 Novel Manufacturing Platform Analysis

8. Probability of Success and Risk Analysis

• 8.1 Clinical Success Probability Modeling
• 8.2 Phase Transition Probability Analysis
• 8.3 Risk-Adjusted Pipeline Valuation
• 8.4 Attrition Rate Assessment
• 8.5 Key Risk Factors
  • 8.5.1 Manufacturing Failures
  • 8.5.2 Patient Eligibility Constraints
  • 8.5.3 Toxicity Management Challenges
  • 8.5.4 Reimbursement and Access Barriers
• 8.6 Sensitivity and Scenario Analysis

9. Commercial and Market Dynamics

• 9.1 Commercialization Landscape
• 9.2 Launch Timeline Forecasting
• 9.3 Probability-Weighted Revenue Forecasts
• 9.4 Peak Sales Opportunity Analysis
• 9.5 Pricing and Reimbursement Trends
• 9.6 Treatment Center Capacity Analysis
• 9.7 Competitive Positioning of Leading Assets

10. Geographic Analysis

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 Latin America
• 10.5 Middle East and Africa

11. Company Profiles

• 11.1 Bristol Myers Squibb
  • 11.1.1 Overview
  • 11.1.2 Financials
  • 11.1.3 TIL Therapy Portfolio
  • 11.1.4 Manufacturing Capabilities
  • 11.1.5 Recent Developments
• 11.2 Instil Bio, Inc.
• 11.3 Obsidian Therapeutics, Inc.
• 11.4 Turnstone Biologics Corp.
• 11.5 Lyell Immunopharma, Inc.
• 11.6 PACT Pharma, Inc.
• 11.7 Lion TCR Pte Ltd
• 11.8 Alaunos Therapeutics, Inc.
• 11.9 Iovance Biotherapeutics, Inc.
• 11.10 Merck & Co., Inc.

12. Deals and Investment Landscape

• 12.1 Licensing Agreements
• 12.2 Co-Development Partnerships
• 12.3 Mergers and Acquisitions
• 12.4 Venture Capital and Public Financing
• 12.5 Manufacturing Facility Investments
• 12.6 Strategic Cell Therapy Collaborations

13. Future Outlook and Strategic Insights

• 13.1 Expansion Beyond Melanoma
• 13.2 Automation and Manufacturing Scale-Up
• 13.3 Combination with Checkpoint Inhibitors
• 13.4 Allogeneic and Gene-Edited TIL Innovations
• 13.5 Strategic Recommendations

14. Methodology and Data Framework

• 14.1 Data Sources
• 14.2 Clinical Trial Validation Framework
• 14.3 Pipeline Inclusion Criteria
• 14.4 Market Modeling and Forecasting Approach
• 14.5 Probability Adjustment Methodology
• 14.6 Limitations and Assumptionss